The Medical Journal of Australia ISSN: 0025-729X 4 February 2013 198 2 72-73 ©The Medical Journal of Australia 2013 www.mja.com.au Editorials amilial hypercholesterolaemia (FH) is the most common and serious type of inherited hyperlipidaemia. It causes premature atherosclerotic cardiovascular disease (CVD), in particular coronary heart disease (CHD), bringing forward the onset of CVD by one to four decades. 1 Although early detection and management can slow the progression of atherosclerosis, there are concerns that the majority of people with FH in Australia and New Zealand are undiagnosed and those diagnosed are often undertreated.
1 Similarly, in the United Kingdom, HEART UK, which supports patients with FH, reported recently that only 15% of patients with FH in the UK were aware they had the condition. In addition, a third of 455 respondents to an online survey did not know that abnormal cholesterol levels could be inherited (http://heartuk.org.uk/latest-news/article/heart-ukextremely-concerned-by-research-highlighting-cholesterol-ignorance).
In 2011, in response to this gap in coronary prevention, the Australian Atherosclerosis Society's FH Australasia Network published a consensus model of care for FH.
1 The model includes guidelines for case detection and cascade screening, assessment and treatment of children and adolescents, and lifestyle and drugtreatment strategies, as well as indications for lowdensity lipoprotein (LDL) cholesterol apheresis (a process similar to haemodialysis to remove LDL cholesterol from the blood). The model of care has been endorsed by the National Heart Foundation, the Cardiovascular Genetics Council and Cardiovascular Nursing Council of the Cardiac Society of Australia and New Zealand, and the Australasian Association of Clinical Biochemists.
1
FH is an autosomal dominant disorder caused by gene mutations encoding the LDL cholesterol receptor and, less commonly, mutations encoding apolipoprotein B-100 (apoB-100) and proprotein convertase subtilisin/ kexin 9 (PCSK9).
1 It is manifest by levels of LDL cholesterol > 5.0 mmol/L, premature CDH and clinical signs of LDL cholesterol deposition (arcus senilis, tendon and cutaneous xanthomas and xanthelasmas). Treatment with high doses of statins, in combination with ezetimibe (a lipid-lowering drug which inhibits intestinal absorption of cholesterol and phytosterols), is widely accepted as cost-effective and may lower plasma LDL cholesterol levels by 65%-75% (to normal levels), thus providing normal life expectancy. 1, 4, 5 However, many patients with FH receive suboptimal treatment, and premature CHD still occurs in this group, as well as in those with poor adherence to therapy. Heavy cigarette smokers are particularly at risksmoking is especially dangerous in FH, partly through a prothrombotic effect.
For patients with FH whose LDL cholesterol levels remain above target after lipid-lowering treatment (2-4 mmol/L, depending on baseline risk 1 ), two new injectable therapies can safely and effectively lower LDL cholesterol levels: monoclonal antibodies to PCSK9 and antisense oligonucleotides to apoB-100 messenger RNA.
1 These may be particularly useful in patients intolerant to statins, and longer-term clinical outcomes, safety, acceptability and cost-effectiveness are currently under investigation. In addition, LDL cholesterol apheresis is available in Victoria, New South Wales and Western Australia for the small number of patients with homozygous FH, or heterozygous FH with uncontrolled hypercholesterolaemia and progressive CHD. 7 This should be combined with genetic testing of FH within families after detection of a mutation in an index case.
1,3 Such a national program promises to reap the benefits of modern DNA technology, and the efficacy of current lipid-lowering therapy, to achieve a normal life expectancy for those with FH.
